Maravai Lifesciences Holdings Stock Alpha and Beta Analysis
| MRVI Stock | USD 4.95 0.01 0.20% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Maravai Lifesciences Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Maravai Lifesciences over a specified time horizon. Remember, high Maravai Lifesciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Maravai Lifesciences' market risk premium analysis include:
Beta 0.75 | Alpha (0.42) | Risk 5.21 | Sharpe Ratio (0.02) | Expected Return (0.12) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Maravai |
Maravai Lifesciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Maravai Lifesciences market risk premium is the additional return an investor will receive from holding Maravai Lifesciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Maravai Lifesciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Maravai Lifesciences' performance over market.| α | -0.42 | β | 0.75 |
Maravai Lifesciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Maravai Lifesciences' Buy-and-hold return. Our buy-and-hold chart shows how Maravai Lifesciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Maravai Lifesciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Maravai Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Maravai Lifesciences shares will generate the highest return on investment. By understating and applying Maravai Lifesciences stock market price indicators, traders can identify Maravai Lifesciences position entry and exit signals to maximize returns.
Maravai Lifesciences Return and Market Media
The median price of Maravai Lifesciences for the period between Sat, Nov 9, 2024 and Fri, Feb 7, 2025 is 5.45 with a coefficient of variation of 14.62. The daily time series for the period is distributed with a sample standard deviation of 0.81, arithmetic mean of 5.54, and mean deviation of 0.54. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Resumen Maravai LifeSciences planea adquirir la empresa de ADN y ARN de Officinae Bio y fomentar la investigacin en terapias innovadoras basadas en cidos nuclei... | 11/08/2024 |
2 | Acquisition by Rebecca Buzzeo of 288198 shares of Maravai Lifesciences subject to Rule 16b-3 | 11/29/2024 |
3 | Acquisition by Lucier Gregory T of 20645 shares of Maravai Lifesciences subject to Rule 16b-3 | 12/09/2024 |
4 | Maravai LifeSciences SWOT analysis stock faces challenges amid growth potential | 12/10/2024 |
5 | Acquisition by Eckert R Andrew of 134409 shares of Maravai Lifesciences subject to Rule 16b-3 | 12/16/2024 |
6 | Maravai LifeSciences reduces debt by 228 million | 12/18/2024 |
7 | Disposition of 32042 shares by Peter Leddy of Maravai Lifesciences at 4.56 subject to Rule 16b-3 | 01/15/2025 |
8 | Maravai LifeSciences Holdings, Inc. Stock An Under 5 Gem with Biggest Upside Potential | 01/21/2025 |
9 | 12 West Capital Management LP Reduces Stake in Maravai LifeSciences Holdings Inc - GuruFocus.com | 01/28/2025 |
10 | Maravai LifeSciences Stock Price Down 7.1 percent - Whats Next - MarketBeat | 01/30/2025 |
11 | Disposition of 25000 shares by Kurt Oreshack of Maravai Lifesciences at 5.03 subject to Rule 16b-3 | 01/31/2025 |
12 | TriLink BioTechnologies geht Partnerschaft mit Avantor ein, um Verfgbarkeit von Nukleinsure-Lsungen in Europa zu erweitern | 02/03/2025 |
13 | Samenvatting TriLink BioTechnologies en Aldevron sluiten niet-exclusieve licentie- en leveringsovereenkomst voor CleanCap mRNA-cappingtechnologie | 02/05/2025 |
About Maravai Lifesciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Maravai or other stocks. Alpha measures the amount that position in Maravai Lifesciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0176 | 0.0157 | Price To Sales Ratio | 3.44 | 3.27 |
Maravai Lifesciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Maravai Lifesciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Maravai Lifesciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Maravai Lifesciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Maravai Lifesciences. Please utilize our Beneish M Score to check the likelihood of Maravai Lifesciences' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Maravai Lifesciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Maravai Lifesciences Backtesting, Maravai Lifesciences Valuation, Maravai Lifesciences Correlation, Maravai Lifesciences Hype Analysis, Maravai Lifesciences Volatility, Maravai Lifesciences History and analyze Maravai Lifesciences Performance. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Maravai Lifesciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.